AVROBIO AVRO 深 滬
等待開盤 07-19 09:30:00 美东时间
1.40
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 1.40
- 總市值 6280.47万
- 52周最高 19.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 10.5612
- 委 比 0.00%
- 總股本 4486.05万
- 歷史最高 644.40
- 量 比 0
- 振 幅 0.00%
- 歷史最低 6.72
- 每 手 1
- 風險率 1.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics, a clinical-stage biotech company focused on treating immune dysregulation, announced that its management will participate in two investor conferences: the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025, and the BTIG Virtual Biotechnology Conference 2025 on July 29-30, 2025. The company’s lead asset, AVTX-009, is a humanized monoclonal antibody targeting IL-1β for inflammatory diseases. Webcasts and re...
06-23 11:00
AVRO India Ltd. Sees GST Proceedings Dropped, No Financial Impact
An update from AVRO India Ltd. ( ($IN:AVROIND) ) is now available. AVRO India L...
02-16 04:43
Tectonic announces ~$185M capital raise
Tectonic Therapeutic (NASDAQ:TECX) has announced a ~$185M capital raise to fund the clinical development of its drug candidates. Pursuant to the terms of the securities purchase agreement, at the clos...
02-03 21:06
Avro India Limited Holds Virtual EGM with Key Stakeholders
An announcement from AVRO India Ltd. ( ($IN:AVROIND) ) is now available. Avro I...
01-20 02:24
Tectonic started at outperform by Raymond James, TX45 cited
Raymond James has started coverage of Tectonic Therapeutic (NASDAQ:TECX) with an outperform rating, citing its drug candidate TX45. The investment firm said it believes the company's relaxin mimetic d...
2024-11-21 01:45
AVROBIO GAAP EPS of -$1.20
AVROBIO press release (NASDAQ:TECX): Q3 GAAP EPS of -$1.20. Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 More on AVROBIO Tect...
2024-11-08 13:21
Tectonic draws bullish view at Wells Fargo on lead asset
Tectonic Therapeutic (NASDAQ:TECX) traded higher on Thursday after Wells Fargo launched its coverage with an Overweight recommendation and a $55 per share target, mainly highlighting its lead candidat...
2024-08-23 01:56
Tectonic gets FDA okay to begin clinical testing for lead drug TX45
Tectonic Therapeutics (NASDAQ:TECX) said it has received FDA clearance for its Investigational New Drug application for TX45 for the treatment of a type of pulmonary hypertension. The company said it ...
2024-07-31 06:54
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
CAMBRIDGE, Mass., June 24, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disea...
2024-06-24 20:58
Avrobio Merges with Tectonic, Emerges as Tectonic Therapeutic
The latest announcement is out from Avrobio (AVRO). AVROBIO has finalized its m...
2024-06-21 05:04
